Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verve Therapeutics Inc VERV

Healthcare Biotechnology
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering... see more

Recent & Breaking News (NDAQ:VERV)

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics

Newsfile October 24, 2024

The Schall Law Firm Encourages Investors To Join A Securities Fraud Case Against Verve Therapeutics, Inc.

Accesswire October 24, 2024

VERV FINAL DEADLINE: RLF, NATIONAL INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm - VERV

Newsfile October 23, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit - VERV

Accesswire October 23, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV

Accesswire October 23, 2024

Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Accesswire October 23, 2024

Investors Who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class Action - VERV

Accesswire October 23, 2024

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV

PR Newswire October 23, 2024

Shareholders that Lost Money on Verve Therapeutics, Inc. (VERV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire October 23, 2024

VERV Shareholders Have Opportunity to Lead Verve Therapeutics, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!

Accesswire October 23, 2024

Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV

PR Newswire October 23, 2024

VERV IMPORTANT DEADLINE: RLF, Global Investor Counsel, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm - VERV

Newsfile October 22, 2024

Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV

Accesswire October 22, 2024

Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire October 22, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics

Accesswire October 22, 2024

October 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VERV

Accesswire October 22, 2024

The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Verve Therapeutics, Inc.

Accesswire October 22, 2024

Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire October 22, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!

Accesswire October 22, 2024

Shareholders that lost money on Verve Therapeutics, Inc.(VERV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire October 21, 2024